14 results about "Acute cardiac failure" patented technology

The present invention discloses a method for predicting ECG signals for patients with acute heart failure, comprising: obtaining historical ECG signals of patients with acute heart failure and generating a multimodal signal including a feature-enhanced ECG signal, dynamic features, and power spectral density, thereby constructing an acute heart failure sample dataset; obtaining a pre-trained ECG signal prediction model, and training the model using the acute heart failure sample dataset based on transfer learning to obtain an acute heart failure ECG signal prediction model; obtaining the ECG signals of patients with acute heart failure in real time and preprocessing them to obtain a real-time multimodal signal, which is used as input to predict ECG signals within a preset time period in the future. By extracting the multimodal signal as the model input, the prediction accuracy and robustness of the ECG signal are significantly improved; based on transfer learning, efficient and accurate ECG signal prediction is achieved in the acute heart failure scenario.

The present invention relates to the technical field of heart sound health detection, and particularly relates to a method for identifying abnormal heart sounds in patients with early acute heart failure. The present invention obtains the first heart sound moment and the second heart sound moment of a sample heart sound signal, determines a window combination based on the position distribution of two types of sliding windows on the sample heart sound signal; according to the similarity between the cardiac cycle in which the short sliding window in the window combination of the sample heart sound signal is located and its neighboring cardiac cycles, and the distance between the short sliding window and the cardiac window cycle in which it is located, the feature vectors of the sliding windows in the window combination are fused to obtain a fusion vector; a hidden Markov model is constructed based on the fusion vector of the window combination of the sample heart sound signal, and the heart sound signal of the patient to be measured is segmented by using the hidden Markov model, and then the heart sound abnormality of the patient to be measured is detected. The present invention fuses the features of different-scale sliding windows of the sample heart sound signal, and improves the accuracy of heart sound signal segmentation.

The present invention discloses the use of a compound of formula I sertaconazole or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating oxidative stress-related cardiovascular diseases. Specifically, the present invention relates to the use of said compound in the preparation of a medicament for preventing or treating oxidative stress-related vascular diseases, including but not limited to acute coronary syndrome, alcoholic heart dysfunction, hypoxic pulmonary arterial hypertension, heart failure, drug-induced cardiotoxicity and stroke, especially acute heart failure.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating acute heart failure and a preparation method thereof. A compound formed by combining propylene glycol monooleate and cathepsin K covers the surface of a mesoporous carbon sphere with a high specific surface area, freezing nano spray drying is performed, the obtained nano particles adsorb a repair promoting solution, and the prepared load reducing particles can target myocardial cells for treatment; after aesculus chinensis, affine cudweed and witch hazel are crushed and extracted, the obtained blood vessel expanding extract is mixed with a blood circulation promoting solution, blood vessels are effectively expanded, the blood flow volume is increased, sodium carboxymethyl cellulose is modified by hydrochloric acid and then reacts with calcium carbonate, and formed modified calcium carboxymethyl cellulose is high in disintegration performance; the anti-infection and side effect reducing agent is sprayed on the surface of the tablet for treating acute heart failure, and the prepared traditional Chinese medicine composition for treating acute heart failure has the advantages of high disintegration speed, comprehensive and efficient treatment effect, long-acting effect, strong drug stability and high bioavailability.

Embodiments disclosed herein establish relationships between changes in cardiovascular indicators and drug combinations. These relationships are established by tracking causal chains described by linear relationships, from drug combinations to cardiovascular parameters and from cardiovascular parameters to cardiovascular indicators, by measuring the direction and sensitivity of hemodynamic changes caused by changes in cardiovascular parameters (resulting from drug administration). Some embodiments also model myocardial oxygen consumption, which cannot be directly measured, and establish relationships between hemodynamic changes in myocardial oxygen consumption and changes in one or more cardiovascular parameters. Because these embodiments qualitatively and quantitatively establish causal chains from drugs to cardiovascular indicators, they support clinical decision-making, thereby reducing the level of mere guesswork and uncertainty in determining the optimal drug combination for patients with acute heart failure.

The present invention relates to an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment that binds to adrenomedullin, for use in congestion therapy in a patient with congestive hypertension; heart failure, in particular acute heart failure; wherein said anti-ADM antibody or anti-ADM fragment binds to the N-terminal portion (aa 1 to 21) of adrenomedullin YRWSMNNFWGLRSFGCRFGTC (SEA ID NO. 22), and wherein said patient is resistant to diuretics or does not respond to diuretic therapy.

This disclosure provides methods and devices for evaluating a patient's heath by assessing the patient's thermoregulatory response to heat. For example, methods include applying heat to patient skin and measuring rate of temperature change. If the rate of temperature change exceeds a pre-determined threshold, the patient can be identified as suffering from acute heart failure.

The invention belongs to the field of cardiovascular diagnosis, and particularly relates to a cardiovascular diagnosis and risk early warning system and method based on millimeter wave radar monitoring. Synchronous non-inductive monitoring of multi-dimensional parameters such as the body fluid retention index, the heart rate variability, the arrhythmia and the respiratory event of the user during night sleep is achieved. According to the system, through an original multi-mode risk feature incidence matrix and an artificial intelligence time sequence model, the core pathophysiological and physiological index of dynamic balance of body fluid is deeply fused with other physiological signals, and a specific high-risk coupling mode is identified; therefore, early-stage and high-specificity risk early warning of acute myocardial infarction, ischemic cerebral apoplexy and acute heart failure decompensation is realized; according to the invention, the problems of lack of pathophysiological depth and insufficient specificity in the existing early warning technology are solved, and a revolutionary active health management tool is provided for cardiovascular and cerebrovascular high-risk groups.

The invention relates to the technical field of biological medicines, in particular to application of a cream globule epidermal growth factor 8 in preparation of a medicine for treating acute heart failure. The milk fat globule epidermal growth factor 8 or the functional fragment, the modified derivative, the expression promoter and the recombinant protein thereof are used for preparing the acute heart failure treatment medicine, myocardial cell systolic dysfunction can be relieved by inhibiting the increase of the acetylation modification level of intracellular tubulin, and then acute heart failure is treated. Particularly, the acute heart failure without basic heart disease can be quickly improved.

The present research aims at successfully establishing a rat acute heart failure model, observing the heart pathological changes of the animal and detecting the heart and blood related indexes to evaluate the stability of the model, so as to make the rat acute heart failure model with short model making period, stable heart failure characteristics, good repeatability and closeness to clinic, facilitate the further research on the pathogenesis and pathophysiological changes of the acute heart failure model and provide certain basis for how to implement the heart protection intervention measures. The rat acute heart failure model construction method of the present application is to inject acetone and isopropyl alcohol into the vein of the rat, stimulate with electromagnetic waves, frighten with sound, stimulate with formaldehyde and stimulate with potassium permanganate, so as to induce the rat acute heart failure model with short model making period, stable heart failure characteristics, good repeatability and closeness to clinic. The rat acute heart failure model constructed by the present application only needs 10 days, the heart failure characteristics are stable, the model is closer to the clinical symptoms and has high repeatability.

The invention belongs to the technical field of medicines, and discloses application of three drug targets in anti-heart failure treatment drug screening. The target spot is closely related to energy metabolism change occurring in acute heart failure heart tissue with heart injury caused by mechanical stimulation or external force, and the energy metabolism change comprises ACLY, PDHB and BCAT2. The medicine has the beneficial effects that the treatment target of the medicine is obviously changed after the heart failure occurs, and is changed in different areas of heart tissues. The target spot relates to tricarboxylic acid cycle, branched chain amino acid metabolism and fatty acid metabolism, and has important significance in overall regulation and control of cardiac metabolism. The three targets have good application and development prospects in guiding clinical metabolic therapy-based anti-heart failure new drug screening and combined medication strategies. The composition can be used for improving metabolism remodeling of acute heart failure.

According to the supporting device for the acute heart failure patient, the height of the supporting plate of the patient is accurately adjusted through the lifting driving module, and therefore the patient can adjust the overall posture according to the comfort level and the treatment requirement of the patient. And secondly, the horizontal sliding module is arranged to drive the back cushion to reach a proper leaning position of the patient, so that the comfort of the patient is improved, and the breathing condition of the patient is optimized. In addition, the angle adjusting module accurately adjusts the back cushion to reach a proper lifting height, so that the upper body of the patient is properly lifted, the heart blood backflow amount of the patient is reduced, the heart burden is relieved, breathing of the patient is relieved, and the nursing effect is improved. The safety of the patient is further enhanced through the arrangement of the bandage, the upper body of the patient can be fixed to the supporting plate, and accidents possibly caused by body position changes or improper movement are prevented. Therefore, the supporting device for the acute heart failure patient provides comfortable, safe and effective nursing experience for the patient.